BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38598020)

  • 21. Oncogenic Properties of the Antisense lncRNA
    Esposito R; Esposito D; Pallante P; Fusco A; Ciccodicola A; Costa V
    Cancer Res; 2019 May; 79(9):2124-2135. PubMed ID: 30862713
    [No Abstract]   [Full Text] [Related]  

  • 22. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
    Xie M; Xu ZX; Dai M; Zhu YY
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis.
    Pak K; Suh S; Kim SJ; Kim IJ
    Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
    Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
    Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
    Ciampi R; Nikiforov YE
    Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.
    Ming J; Liu Z; Zeng W; Maimaiti Y; Guo Y; Nie X; Chen C; Zhao X; Shi L; Liu C; Huang T
    Int J Clin Exp Pathol; 2015; 8(11):15155-62. PubMed ID: 26823860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
    Leeman-Neill RJ; Brenner AV; Little MP; Bogdanova TI; Hatch M; Zurnadzy LY; Mabuchi K; Tronko MD; Nikiforov YE
    Cancer; 2013 May; 119(10):1792-9. PubMed ID: 23436219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
    Meng C; Gao J; Liang J; Liang ZY; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer.
    Lin AJ; Samson P; DeWees T; Henke L; Baranski T; Schwarz J; Pfeifer J; Grigsby P; Markovina S
    Cancer Med; 2019 Jan; 8(1):437-446. PubMed ID: 30552739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RET polymorphisms might be the risk factors for thyroid cancer.
    Huang RX; Yang F
    Int J Clin Exp Pathol; 2015; 8(5):5793-7. PubMed ID: 26191299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of RET genetic polymorphisms and haplotypes with papillary thyroid carcinoma in the Portuguese population: a case-control study.
    Santos M; Azevedo T; Martins T; Rodrigues FJ; Lemos MC
    PLoS One; 2014; 9(10):e109822. PubMed ID: 25330015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
    Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
    Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.